RSV Prevention Products Show Effectiveness in US Infants

Maternal respiratory syncytial virus vaccination and infant receipt of nirsevimab were estimated to protect infants from associated hospitalizations during their first season in 2024-2025.
Medscape Medical News

source https://www.medscape.com/viewarticle/maternal-rsv-vaccine-and-nirsevimab-show-effectiveness-us-2026a10000ah?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors